|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein显示文摘最新新兴的中东呼吸症候群 coronavirus (MERS-CoV ) 能在人引起严重、致命的急性呼吸疾病。尽管有全球努力,潜力为一联系在未来流行不能被排除。有效相对的措施的发展是迫切的。MERS-CoV-specific 抗病毒的药或疫苗是还没可得到的。使用 MERS-CoV (MERS-RBD ) 的尖铁受体绑定领域使老鼠免疫,我们识别了二抵销 monoclonal 抗体(mAbs ) 4C2 和 2E6。两 mAbs potently 与高功效在 vitro 绑在 MERS-RBD 和块病毒入口。我们进一步由使在 Fab 碎片和 RBD 之间的建筑群结晶调查了他们中立化的机制,并且解决了 4C2 Fab/MERS-RBD 建筑群的结构。结构证明 4C2 认出部分重叠的 epitope 在 MERS-RBD 的受体绑定脚印,从而由位的阻碍者和接口残余竞争防碍病毒 / 受体相互作用。2E6 也堵住受体绑定,并且为绑定与 4C2 竞争到 MERS-RBD。基于结构,我们进一步由保存仅仅 paratope 残余并且从人的免疫球蛋白与对应物代替留下的氨基酸使 4C2 人性化。人性化的 4C2 (4C2h ) 抗体支撑了类似的抵销的活动和生物化学的特征到父母老鼠抗体。最后,我们证明 4C2h 能显著地在感染 MERS-CoV 的 Ad5-hCD26-transduced 鼠标的肺消除病毒 titers,因此在临床的设置为预防和治疗代表一个有希望的代理人。 | Yan Li YuhuaWan Peipei Liu Jincun Zhao Guangwen Lu Jianxun Qi Qihui Wang Xuancheng LU Ying Wu Weniun Liu Buchang Zhang Kwok-Yung Yuen Stanley Perlman George F Gao Jinghua Yan | 2015 | Cell Research2015，25，11： | 14 |
| 2 | Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2显示文摘Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused a global crisis,urgently necessitating the development of safe,efficacious,convenient-to-store,and low-cost vaccine options.A major challenge is that the receptor-binding domain(RBD)-only vaccine fails to trigger long-lasting protective immunity if used alone for vaccination. | Shiyu Sun Yueqi Cai Tian-Zhang Song Yang Pu Lin Cheng Hairong Xu Jing Sun Chaoyang Meng Yifan Lin Haibin Huang Fang Zhao Silin Zhang Yu Gao Jian-Bao Han Xiao-Li Feng Dan-Dan Yu Yalan Zhu Pu Gao Haidong Tang Jincun Zhao Zheng Zhang Jiaming Yang Zhenxiang Hu Yang-Xin Fu Yong-Tang Zheng Hua Peng | 2021 | Cell Research2021，31，9： | 7 |
| 3 | Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients显示文摘Dear Editor,In 2019,a zoonotic coronavirus named severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)was identified as the causative agent of Coronavirus Disease 2019(COVID-19).As of 8 June 2020,the World Health Organization(WHO)has reported 6,912,751 globally confirmed cases with 400,469 deaths.Although generally causes mild disease,SARS-CoV-2 infection can result in serious outcomes,including acute lung injury(ALI)and acute respiratory distress syndrome(ARDS),the leading cause of mortality in patients with comorbidities.Recent autopsy studies of COVID-19 patients revealed mononuclear infiltration and excessive production of mucus in the infected lung,especially in the damaged small airways and alveoli(Bian and Team,2020;Liu et al.,2020). | Jiangping He Shuijiang Cai Huijian Feng Baomei Cai Lihui Lin Yuanbang Mai Yinqiang Fan Airu Zhu Huang Huang Junjie Shi Dingxin Li' Yuanjie Wei Yueping Li Yingying Zhao’ Yuejun Pan He Liu Xiaoneng Mo Xi He Shangtao Cao FengYu Hu Jincun Zhao Jie Wang Nanshan Zhong Xinwen Chen Xilong Deng Jiekai Chen | 2020 | Protein & Cell2020，11，9： | 7 |
| 4 | Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults显示文摘Dear Editor,To May 2022,the COVID-19 pandemic has claimed more than 6.28 million lives,with more than 524 million confirmed cases worldwide.The recent emergence of highly transmissible Omicron variant of severe acute respiratory syndrome coronavirus 2(SARSCoV-2)has triggered another major surge in both confirmed cases and deaths.1 Ten COVID-19 vaccines have been approved by the World Health Organization(WHO)for emergency use,including the two mRNA vaccines,BNT162b2 and mRNA-1273,and two Chinese inactivated vaccines,CoronaVac and BBIBP-CorV.However,the rapid waning of vaccine-induced virus-neutralizing antibody titers and the continuous emergence of variants of concern(VOCs),including Alpha,Beta,Delta and Omicron,have created unprecedented challenges in the eradication of COVID-19 pandemic.2–4. | Xiaoqiang Liu Yuhua Li Zhongfang Wang Shouchun Cao Weijin Huang Lin Yuan Yi-Jiao Huang Yan Zheng Jingjing Chen Bo Ying Zuoyun Xiang Jin Shi Jincun Zhao Zhen Huang Cheng-Feng Qin | 2022 | Cell Research2022，32，8： | 5 |
| 5 | A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice,rabbits and NHPs显示文摘The emergence of SARS-CoV-2 variants and potentially other highly pathogenic sarbecoviruses in the future highlights the need for pan-sarbecovirus vaccines.Here,we discovered a new STING agonist,CF501,and found that CF501-adjuvanted RBD-FC vaccine(CF501/RBD-FC)elicited significantly stronger neutralizing antibody(nAb)and T cell responses than Alum-and cGAMP-adjuvanted RBD-FC in mice.Vaccination of rabbits and rhesus macaques(nonhuman primates,NHPs)with CF501/RBD-FC elicited exceptionally potent nAb responses against SARS-CoV-2 and its nine variants and 41 S-mutants,SARS-CoV and bat SARSr-CoVs.CF501/RBD-FC-immunized hACE2-transgenic mice were almost completely protected against SARS-CoV-2 challenge,even 6 months after the initial immunization.NHPs immunized with a single dose of CF501/RBD-FC produced high titers of nAbs.The immunized macaques also exhibited durable humoral and cellular immune responses and showed remarkably reduced viral load in the upper and lower airways upon SARS-CoV-2 challenge even at 108 days post the final immunization.Thus,CF501/RBD-Fc can be further developed as a novel pan-sarbecovirus vaccine to combat current and future outbreaks of sarbecovirus diseases. | Zezhong Liu Jie Zhou Wei Xu Wei Deng Yanqun Wang Meiyu Wang Qian Wang Ming Hsieh Jingming Dong Xinling Wang Weijin Huang Lixiao Xing Miaoling He Chunlin Tao Youhua Xie Yilong Zhang Youchun Wang Jincun Zhao Zhenghong Yuan Chuan Qin Shibo Jiang Lu Lu | 2022 | Cell Research2022，32，3： | 5 |
| 6 | Main protease of SARS-CoV-2 serves as a bifunctional molecule in restricting type I interferon antiviral signaling显示文摘Dear Editor,At present,the world is suffering from an ongoing pandemic of 2019 novel coronavirus(COVID-19)which is caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2/2019-nCoV).To date,>20 million cases were confirmed with a death toll at>700,000.Although there are no clinically specific and effective antiviral treatments toward SARS-CoV-2 infection so far,the pathological study of SARS-CoV-2 infection and the development of SARS-CoV-2-specific vaccines are progressing rapidly within these several months.1 However,few reports mentioned the mechanism employed by SARS-CoV-2 for evading from surveillance of immune system. | Yaoxing Wu Ling Ma Zhen Zhuang Sihui Cai Zhiyao Zhao Lingli Zhou Jing Zhang Pei-Hui Wang Jincun Zhao Jun Cui | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 4 |
| 7 | A core-shell structured COYID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity显示文摘Although inoculation of COVID-19 vaccines has rolled out globally,there is still a critical need for safe and effective vaccines to ensure fair and equitable supply for all countries.Here,we report on the development of a highly efficacious mRNA vaccine,SW0123 that is composed of sequence-modified mRNA encoding the full-length SARS-CoV-2 Spike protein packaged in core-shell structured lipopolyplex(LPP)nanoparticles.SWOT 23 is easy to produce using a large-scale microfluidics-based apparatus.The unique core-shell structured nanoparticle facilitates vaccine uptake and demonstrates a high colloidal stability,and a desirable biodistribution pattern with low liver targeting effect upon intramuscular administration.Extensive evaluations in mice and nonhuman primates revealed strong immunogenicity of SW0123,represented by induction of Th1-polarized T cell responses and high levels of antibodies that were capable of neutralizing not only the wild-type SARS-CoV-2,but also a panel of variants including D614G and N501Y variants.In addition,SW0123 conferred effective protection in both mice and non-human primates upon SARS-CoV-2 challenge.Taken together,SW0123 is a promising vaccine candidate that holds prospects for further evaluation in humans. | Ren Yang Yao Deng Baoying Huang Lei Huang Ang Lin Yuhua Li Wenling Wang Jingjing Liu Shuaiyao Lu Zhenzhen Zhan Yufei Wang Ruhan A Wen Wang Peihua Niu Li Zhao Shiqiang Li Xiaopin Ma Luyao Zhang Yujian Zhang Weiguo Yao Xingjie Liang Jincun Zhao Zhongmin Liu Xiaozhong Peng Hangwen Li Wenjie Tan | 2021 | Signal Transduction and Targeted Therapy2021，6，6： | 3 |
| 8 | Three-dimensional path following control system for net cage inspection using bionic robotic fish显示文摘With the increasing impacts of overfishing and environmental pollution,the deep-sea cage culture of marine fishes has become an important direction of mariculture.In this paper,a tuna-like robotic fish with a three-dimensional helix path-following control system is designed for deep-sea net cage inspection.To mimic the flexibility of the fish’s movement,the kinematic model of the robotic fish adopts a tuna-like double-joint design with an addi-tional thruster device at the tail.Since the descending interval control plays a critical role in deep-sea net cage inspection,the control system utilizes the proportion integration differ-entiation(PID)based fuzzy logic control method to control the descending interval and yaw angle during the helix path movement.A polar coordinate path definition method is also proposed to simplify the reference path definition during net cage inspection.The experi-mental results demonstrates that the proposed three-dimensional path-following model can conduct net inspection task in an interferential environment and move along prede-fined reference path. | Yuanrong Chen Jingfen Qiao Jincun Liu Ran Zhao Dong An Yaoguang Wei | 2022 | Information Processing in Agriculture2022，9，1： | 2 |
| 9 | RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein facilitates NF-kB hyper-activation and inflammation显示文摘The ongoing 2019 novel coronavirus disease(COVID-19)caused by SARS-CoV-2 has posed a worldwide pandemic and a major global public health threat.The severity and mortality of COVID-19 are associated with virus-induced dysfunctional inflammatory responses and cytokine storms.However,the interplay between host inflammatory responses and SARS-CoV-2 infection remains largely unknown.Here,we demonstrate that SARS-CoV-2 nucleocapsid(N)protein,the major structural protein of the virion,promotes the virus-triggered activation of NF-kB signaling.After binding to viral RNA,N protein robustly undergoes liquid-liquid phase separation(LLPS),which recruits TAK1 and IKK complex,the key kinases of NF-kB signaling,to enhance NF-kB activation.Moreover,1,6-hexanediol,the inhibitor of LLPS,can attenuate the phase separation of N protein and restrict its regulatory functions in NF-kB activation.These results suggest that LLPS of N protein provides a platform to Induce NF-kB hyper-activation,which could be a potential therapeutic target against COVID-19 severe pneumonia. | Yaoxing Wu Ling Ma Sihui Cai Zhen Zhuang Zhiyao Zhaou Shouheng Jin Weihong Xie Lingli Zhou Lei Zhang Jincun Zhao Jun Cui | 2021 | Signal Transduction and Targeted Therapy2021，6，5： | 2 |
| 10 | Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5,BQ.1,BQ.1.1,BF.7 and BA.2.75.2显示文摘Dear Editor,Recently,a number of new Omicron subvariants related to BA.4/5 and BA.2.75 have emerged and shown remarkable antibody evasion capacities,in particular BF.7,BQ.1,BQ.1.1,BA.2.75.2,XBB and XBB.1.5.1 Unsurprisingly,these new subvariants are quickly gaining prevalence worldwide.In fact,some of them have outcompeted BA.5 in the USA according to CDC’s national genomic surveillance data in which,as of 6th February 2023,XBB.1.5,BQ.1.1,BQ.1,XBB and BF.7 have achieved a dominance of 66.4%,19.9%,7.3%,2.3%and 0.5%in the USA,as compared to 0.5%for BA.5.In this report,using plasma samples collected from individuals following different vaccination strategies and COVID-19 convalescent donors,we performed pseudoviral neutralization assays to confirm severe reductions in neutralization titers against BF.7,BQ.1,BQ.1.1,BA.2.75.2,XBB and XBB.1.5 in comparison to other Omicron sub-lineages.XBB and XBB.1.5 were shown to be remarkably resistant to plasma neutralization in all tested cohorts.By comparing the differential neutralization profiles,we found that a heterologous booster with an aerosolized vaccine following 2 doses of inactivated vaccine seemed to be superior to other vaccination strategies. | Airu Zhu Peilan Wei Miao Man Xuesong Liu Tianxing Ji Jiantao Chen Canjie Chen Jiandong Huo Yanqun Wang Jincun Zhao | 2023 | Signal Transduction and Targeted Therapy2023，8，4： | 1 |
| 11 | SARS-CoV-2 nucleocapsid protein triggers hyperinflammation via protein-protein interaction-mediated intracellular Cl^(−) accumulation in respiratory epithelium显示文摘SARS-CoV-2,the culprit pathogen of COVID-19,elicits prominent immune responses and cytokine storms.Intracellular Cl^(−)is a crucial regulator of host defense,whereas the role of Cl^(−)signaling pathway in modulating pulmonary inflammation associated with SARS-CoV-2 infection remains unclear.By using human respiratory epithelial cell lines,primary cultured human airway epithelial cells,and murine models of viral structural protein stimulation and SARS-CoV-2 direct challenge,we demonstrated that SARS-CoV-2 nucleocapsid(N)protein could interact with Smad3,which downregulated cystic fibrosis transmembrane conductance regulator(CFTR)expression via microRNA-145.The intracellular Cl^(−)concentration([Cl^(−)]i)was raised,resulting in phosphorylation of serum glucocorticoid regulated kinase 1(SGK1)and robust inflammatory responses.Inhibition or knockout of SGK1 abrogated the N protein-elicited airway inflammation.Moreover,N protein promoted a sustained elevation of[Cl^(−)]i by depleting intracellular cAMP via upregulation of phosphodiesterase 4(PDE4).Rolipram,a selective PDE4 inhibitor,countered airway inflammation by reducing[Cl^(−)]i.Our findings suggested that Cl^(−)acted as the crucial pathological second messenger mediating the inflammatory responses after SARS-CoV-2 infection.Targeting the Cl^(−)signaling pathway might be a novel therapeutic strategy for COVID-19. | Lei Chen Wei-Jie Guan Zhuo-Er Qiu Jian-Bang Xu Xu Bai Xiao-Chun Hou Jing Sun Su Qu Ze-Xin Huang Tian-Lun Lei Zi-Yang Huang Jincun Zhao Yun-Xin Zhu Ke-Nan Ye Zhao-Rong Lun Wen-Liang Zhou Nan-Shan Zhong Yi-Lin Zhang | 2022 | Signal Transduction and Targeted Therapy2022，7，8： | 1 |
| 12 | Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis,prognosis and drug target discovery显示文摘Disease progression prediction and therapeutic drug target discovery for Coronavirus disease 2019(COVID-19)are particularly important,as there is still no effective strategy for severe COVID-19 patient treatment.Herein,we performed multi-platform omics analysis of serial plasma and urine samples collected from patients during the course of COVID-19.Integrative analyses of these omics data revealed several potential therapeutic targets,such as ANXA1 and CLEC3B.Molecular changes in plasma indicated dysregulation of macrophage and suppression of T cell functions in severe patients compared to those in non-severe patients.Further,we chose 25 important molecular signatures as potential biomarkers for the prediction of disease severity.The prediction power was validated using corresponding urine samples and plasma samples from new COVID-19 patient cohort,with AUC reached to 0.904 and 0.988,respectively.In conclusion,our omics data proposed not only potential therapeutic targets,but also biomarkers for understanding the pathogenesis of severe COVID-19. | Yuming Li Guixue Hou Haibo Zhou Yanqun Wang Hein Min Tun Airu Zhu Jingxian Zhao Fei Xiao Shanwen Lin Dongdong Liu Dunrong Zhou Lang Mai Lu Zhang Zhaoyong Zhang Lijun Kuang Jiao Guan Qiushi Chen Liyan Wen Yanjun Zhang Jianfen Zhuo Fang Li Zhen Zhuang Zhao Chen Ling Luo Donglan Liu Chunke Chen Mian Gan Nanshan Zhong Jincun Zhao Yan Ren Yonghao Xu | 2021 | Signal Transduction and Targeted Therapy2021，6，5： | 1 |
| 13 | Longitudinal virological changes and underlying pathogenesis in hospitalized COVID-19 patients in Guangzhou,China显示文摘Prolonged viral RNA shedding and recurrence of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)in coronavirus disease 2019(COVID-19)patients have been reported.However,the clinical outcome and pathogenesis remain unclear.In this study,we recruited 43 laboratory-confirmed COVID-19 patients.We found that prolonged viral RNA shedding or recurrence mainly occurred in severe/critical patients(P<0.05).The average viral shedding time in severe/critical patients was more than 50 days,and up to 100 days in some patients,after symptom onset.However,chest computed tomography gradually improved and complete absorption occurred when SARS-CoV-2 RT-PCR was still positive,but specific antibodies appeared.Furthermore,the viral shedding time significantly decreased when the A1,430G or C12,473T mutation occurred(P<0.01 and FDR<0.01)and increased when G227A occurred(P<0.05 and FDR<0.05).High IL1R1,IL1R2,and TNFRSF21 expression in the host positively correlated with viral shedding time(P<0.05 and false discovery rate<0.05).Prolonged viral RNA shedding often occurs but may not increase disease damage.Prolonged viral RNA shedding is associated with viral mutations and host factors. | Zhengtu Li Yinhu Li Ruilin Sun Shaoqiang Li Lingdan Chen Yangqing Zhan Mingzhou Xie Jiasheng Yang Yanqun Wang Airu Zhu Guoping Gu Le Yu Shuaicheng Li Tingting Liu Zhaoming Chen Wenhua Jian Qian Jiang Xiaofen Su Weili Gu Liyan Chen Jing Cheng Jincun Zhao Wenju Lu Jinping Zheng Shiyue Li Nanshan Zhong Feng Ye | 2021 | Science China(Life Sciences)2021，64，12： | 1 |
| 14 | Phase-separated nucleocapsid protein of SARS-CoV-2 suppresses cGAS-DNA recognition by disrupting cGAS-G3BP1 complex显示文摘Currently,the incidence and fatality rate of SARS-CoV-2 remain continually high worldwide.COVID-19 patients infected with SARS-CoV-2 exhibited decreased type I interferon(IFN-I)signal,along with limited activation of antiviral immune responses as well as enhanced viral infectivity.Dramatic progresses have been made in revealing the multiple strategies employed by SARS-CoV-2 in impairing canonical RNA sensing pathways.However,it remains to be determined about the SARS-CoV-2 antagonism of cGAS-mediated activation of IFN responses during infection.In the current study,we figure out that SARS-CoV-2 infection leads to the accumulation of released mitochondria DNA(mtDNA),which in turn triggers cGAS to activate IFN-I signaling.As countermeasures,SARS-CoV-2 nucleocapsid(N)protein restricts the DNA recognition capacity of cGAS to impair cGAS-induced IFN-I signaling.Mechanically,N protein disrupts the assembly of cGAS with its co-factor G3BP1 by undergoing DNA-induced liquid-liquid phase separation(LLPS),subsequently impairs the double-strand DNA(dsDNA)detection ability of cGAS.Taken together,our findings unravel a novel antagonistic strategy by which SARS-CoV-2 reduces DNA-triggered IFN-I pathway through interfering with cGAS-DNA phase separation. | Sihui Cai Chenqiu Zhang Zhen Zhuang Shengnan Zhang Ling Ma Shuai Yang Tao Zhou Zheyu Wang Weihong Xie Shouheng Jin Jincun Zhao Xiangdong Guan Jianfeng Wu Jun Cui Yaoxing Wu | 2023 | Signal Transduction and Targeted Therapy2023，8，5： | 1 |
| 15 | Therapeutic potential of C1632 by inhibition of SARS-CoV-2 replication and viral-induced inflammation through upregulating let-7显示文摘Dear Editor,The COVID-19 pandemic caused by SARS-CoV-2 has led to acute respiratory distress syndrome(ARDS)with a high rate of death.An excessive inflammatory response,caused by virus infection,is associated with severe clinical manifestations that may lead to death of patients.1 Therefore,the blockage of virus replication and suppression of hyper-inflammatory response are beneficial for COVID-19 treatment.However,the drug targeting both virus and hyper-inflammation,as far as we know,is not available yet. | Chen Xie Yanlian Chen Dongling Luo Zhen Zhuang Heping Jin Haoxian Zhou Xiaocui Li Haijun Lin Xiaohui Zheng Jing Zhang Peihui Wang Jincun Zhao Yong Zhao Hui Huang | 2021 | Signal Transduction and Targeted Therapy2021，6，3： | 1 |
| 16 | A novel luciferase immunosorbent assay performs better than a commercial enzyme-linked immunosorbent assay to detect MERS-CoV specific IgG in humans and animals显示文摘The Middle East respiratory syndrome(MERS)is a lethal zoonosis caused by MERS coronavirus(MERS-CoV)and poses a significant threat to public health worldwide.Therefore,a rapid,sensitive,and specific serologic test for detecting anti-MERS-CoV antibodies in both humans and animals is urgently needed for the successful management of this illness.Here,we evaluated various novel luciferase immunosorbent assays(LISA)based on nucleocapsid protein(NP)as well as fragments derived from spike protein(S)including subunit 1(S1),N terminal domain(NTD),receptorbinding domain(RBD)and subunit 2(S2)of S for the detection of MERS-CoV-specific IgG.Fusion proteins,including nanoluciferase(NLuc)and various fragments derived from the NP or S protein of MERS-CoV,were expressed in human embryonic kidney 293 T cells.LISAs that detected anti-MERS-CoV IgG were further developed using cell lysates expressing various fusion proteins.Panels of human or animal samples infected with MERS-CoV were used to analyze the sensitivity and specificity of various LISAs in reference to a MERS-CoV RT-PCR,commercial S1-based ELISA,and pseudovirus particle neutralization test(ppNT).Our results showed that the S1-,RBD-,and NP-LISAs were more sensitive than the NTD-and S2-LISAs for the detection of anti-MERS-CoV IgG.Furthermore,the S1-,RBD-,and NP-LISAs were more sensitive(by at least 16-fold)than the commercially available S1-ELISA.Moreover,the S1-,RBD-,and NPLISA specifically recognized anti-MERS-CoV IgG and did not cross-react with samples derived from other human CoV(OC43,229E,HKU1,NL63)-infected patients.More importantly,these LISAs proved their applicability and reliability for detecting anti-MERS-CoV IgG in samples from camels,monkeys,and mice,among which the RBD-LISA exhibited excellent performance.The results of this study suggest that the novel MERS-CoV RBD-and S1-LISAs are highly effective platforms for the rapid and sensitive detection of anti-MERS-CoV IgG in human and animal samples.These assays have the potential to be used as serologic tests for the management and control of MERS-CoV infection. | Wenling Wang Tianyu Wang Yao Deng Peihua Niu Ruhan A Jincun Zhao Malik Peiris Shixing Tang Wenjie Tan | 2019 | Biosafety and Health2019，1，3： | 1 |
| 17 | Correction To:Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARSCoV-2 variants显示文摘Correction to:Signal Transduction and Targeted Therapy https://doi.org/10.1038/s41392-023-01423-6,published online 17 April 2023 After online publication of the article^(1),the authors noticed two inadvertent mistakes occurred in References that needs to be corrected.The correct text is provided as follows. | Qian Wang Chenchen Yang Li Yin Jing Sun Wei Wang Hengchun Li Zhengyuan Zhang Si Chen Bo Liu Zijian Liu Linjing Shi Xiaolin Liu Suhua Guan Chunhua Wang Linbing Qu Ying Feng Xuefeng Niu Liqiang Feng Jincun Zhao Pingchao Li Ling Chen Nanshan Zhong | 2023 | Signal Transduction and Targeted Therapy2023，8，6： | 1 |
| 18 | A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding显示文摘Dear Editor,The constant evolution of SARS-CoV-2 has resulted in the emergence of circulating variants during the COVID-19 pandemic.Recently,a newly emerged B.1.1.529(Omicron)variant raised global concern.Compared with the original SARS-CoV-2 strain and other variants of concern(VOCs),the Omicron variant has more than 30 mutations on its spike(S)protein,of which 16 mutations are located in the receptor-binding domain(RBD). | Yingdan Wang Wuqiang Zhan Jiangyan Liu Yanqun Wang Xiang Zhang Meng Zhang Lin Han Yunping Ma Lu Lu Yumei Wen Zhenguo Chen Jincun Zhao Fan Wu Lei Sun Jinghe Huang | 2022 | Cell Research2022，32，9： | 1 |
| 19 | A CRISPR activation screen identifies genes that enhance SARS-CoV-2 infection显示文摘Dear Editor,Identifying the host factors that are utilized for virus infection and mapping their cell-type expression profile can help to understand the viral tissue/organ tropism and pathogenesis.Much effort has been devoted to the identification of SARS-CoV-2 infection-dependent host factors.CRISPR-based activation(Konermann et al.,2015). | Fei Feng Yunkai Zhu Yanlong Ma Yuyan Wang Yin Yu Xinran Sun Yuanlin Song Zhugui Shao Xinxin Huang Ying Liao Jingyun Ma Yuping He Mingyuan Wang Longhai Tang Yaowei Huang Jincun Zhao Qiang Ding Youhua Xie Qiliang Cai Hui Xiao Chun Li Zhenghong Yuan Rong Zhang | 2023 | Protein & Cell2023，14，1： | 0 |
| 20 | P21-activated kinase 1 (PAK1)-mediated cytoskeleton rearrangement promotes SARS-CoV-2 entry and ACE2 autophagic degradation显示文摘Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the causative agent of coronavirus disease 2019(COVID-19),has had a significant impact on healthcare systems and economies worldwide.The continuous emergence of new viral strains presents a major challenge in the development of effective antiviral agents.Strategies that possess broad-spectrum antiviral activities are desirable to control SARS-CoV-2 infection.ACE2,an angiotensin-containing enzyme that prevents the overactivation of the renin angiotensin system,is the receptor for SARS-CoV-2.ACE2 interacts with the spike protein and facilitates viral attachment and entry into host cells.Yet,SARS-CoV-2 infection also promotes ACE2 degradation.Whether restoring ACE2 surface expression has an impact on SARS-CoV-2 infection is yet to be determined.Here,we show that the ACE2-spike complex is endocytosed and degraded via autophagy in a manner that depends on clathrin-mediated endocytosis and PAK1-mediated cytoskeleton rearrangement.In contrast,free cellular spike protein is selectively cleaved into S1 and s2 subunits in a lysosomal-dependent manner.Importantly,we show that the pan-PAK inhibitor FRAX-486 restores ACE2 surface expression and suppresses infection by different SARS-CoV-2 strains.FRAX-486-treated Syrian hamsters exhibit significantly decreased lung viral load and alleviated pulmonary inflammation compared with untreated hamsters.In summary,our findings have identified novel pathways regulating viral entry,as well as therapeutic targets and candidate compounds for controlling the emerging strains of SARS-CoV-2 infection. | Ming Liu Bingtai Lu Yue Li Shuofeng Yuan Zhen Zhuang Guangyu Li Dong Wang Liuheyi Ma Jianheng Zhu Jinglu Zhao Chris Chung-Sing Chan Vincent Kwok-Man Poon Kenn Ka-Heng Chik Zhiyao Zhao Huifang Xian Jingxian Zhao Jincun Zhao Jasper Fuk-Woo Chan Yuxia Zhang | 2023 | Signal Transduction and Targeted Therapy2023，8，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员